Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

Slides:

Advertisements

Similar presentations

Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response Helle Krogh Johansen, Kasper.

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

Dietary supplementation with multiple micronutrients: No beneficial effects in pediatric cystic fibrosis patients Johanna H. Oudshoorn, Peter H.C. Klijn,

Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients Helle Krogh Johansen, Samuel.

Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir

Use of high-dose ibuprofen in a pediatric cystic fibrosis center

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

Lactate in cystic fibrosis sputum

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to β-lactam antibiotics

Pseudomonas aeruginosa in cystic fibrosis: Pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease Malin Carlsson, Swati.

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis M. Proesmans, F. Vermeulen,

D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model K. Thomsen, L. Christophersen, T. Bjarnsholt, P.Ø.

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

A. Oliver, A. Mena Clinical Microbiology and Infection

Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis Malin Carlsson, Leif Eriksson, Tania Pressler, Ragnhild Kornfält,

Fiona K. Dunlevy, S. Lorraine Martin, Francine de Courcey, J

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

Vitamin A and lung function in CF

P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs Oana Ciofu,

Pulmonary nocardiosis in cystic fibrosis

An evaluation strategy for potential QTc prolongation with chronic azithromycin therapy in cystic fibrosis Patrick John Lenehan, Craig M. Schramm, Melanie.

Cytokines in nasal lavages and plasma and their correlation with clinical parameters in cystic fibrosis Marthe S. Paats, Ingrid M. Bergen, Marleen Bakker,

A.H. Gifford Journal of Cystic Fibrosis

Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease Nina Dickerhof, Rufus Turner, Irada Khalilova, Emmanuelle Fantino,

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Physiologic endpoints for clinical studies for cystic fibrosis

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Higher Interleukin-7 serum concentrations in patients with cystic fibrosis correlate with impaired lung function Julia Seyfarth, Sutharsan Sivagurunathan,

Cytokine gene polymorphisms and severity of CF lung disease

Nasal polyposis in lung transplant recipients with cystic fibrosis

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

Soluble inflammation markers in nasal lavage from CF patients and healthy controls Natalie Beiersdorf, Matthias Schien, Julia Hentschel, Wolfgang Pfister,

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis Hanne Vebert Olesen, Uffe Holmskov, Peter Oluf Schiøtz, Grith Lykke Sørensen

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Airway inflammation in mild cystic fibrosis

Treatment intensity and characteristics of MRSA infection in CF

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Cystic fibrosis and pregnancy in the modern era: A case control study

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi, T. Presler, C. Koch, N. Høiby Journal of Cystic Fibrosis Volume 5, Issue 3, Pages 145-151 (August 2006) DOI: 10.1016/j.jcf.2005.12.004 Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 The concentration of PMNs in the blood of CF patients with chronic P. aeruginosa lung infection (n=31) and in non-infected CF patients (n=6). The lines show the medians. Normal reference interval: 1.8–7.4×109 PMNs pr l. Data were analyzed by Mann–Whitney test. Journal of Cystic Fibrosis 2006 5, 145-151DOI: (10.1016/j.jcf.2005.12.004) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 This figure shows the concentration of G-CSF and IL-8 in the sera of CF patients with chronic P. aeruginosa lung infection (n=37) and in non-infected CF patients (n=6). The concentration of cytokines was measured with ELIZA as pg/ml. (A) G-CSF. (B) IL-8. The lines show the medians. Data were analyzed by Mann–Whitney test. Journal of Cystic Fibrosis 2006 5, 145-151DOI: (10.1016/j.jcf.2005.12.004) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 3 Correlation between concentration of G-CSF in the sera and the concentration of TNF-α in the sputum from CF patients with chronic P. aeruginosa lung infection (n=31). Correlation was evaluated by Spearmann Rank test (p<0.006, Rho=0.475). Journal of Cystic Fibrosis 2006 5, 145-151DOI: (10.1016/j.jcf.2005.12.004) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 4 Correlation between the lung function expressed as percentage of predicted value in CF patients with chronic P. aeruginosa lung infection and the concentration of PMNs in the blood (n=29) and the concentration of G-CSF in the sera (n=34). Correlations were evaluated by Spearmann Rank test. (A) PMNs and FEV1 (p<0.03, Rho=−0.400). (B) PMNs and FVC (p<0.03, Rho=−0.421). (C) G-CSF and FEV1 (p<0.009, Rho=−0.458). (D) G-CSF and FVC (p<0.02, Rho=−0.400). Journal of Cystic Fibrosis 2006 5, 145-151DOI: (10.1016/j.jcf.2005.12.004) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 5 The lung function before and after elective antibiotic treatment of 15 CF patients with chronic P. aeruginosa lung infection. Wilcoxon signed pair-differences rank test was used for statistical analysis. Journal of Cystic Fibrosis 2006 5, 145-151DOI: (10.1016/j.jcf.2005.12.004) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 6 The concentration of G-CSF in the sera and PMNs in the peripheral blood before and after elective antibiotic treatment of 15 CF patients with chronic P. aeruginosa lung infection. Wilcoxon signed pair-differences rank test was used for statistical analysis. Journal of Cystic Fibrosis 2006 5, 145-151DOI: (10.1016/j.jcf.2005.12.004) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 7 The expression of CD16 and CD62L on in the peripheral blood before and after elective antibiotic treatment of 15 CF patients with chronic P. aeruginosa lung infection. Wilcoxon signed pair-differences rank test was used for statistical analysis. Journal of Cystic Fibrosis 2006 5, 145-151DOI: (10.1016/j.jcf.2005.12.004) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions